65055-17-6

Basic information

• Product Name: 3-Chloro-4-fluorobenzoyl chloride
• Synonyms: 3-CHLORO-4-FLUOROBENZOYL CHLORIDE;Benzoyl chloride, 3-chloro-4-fluoro- (9CI);3-Chloro-4-fluorobenzoyl chloride 97%;3-Chloro-4-fluorobenzoylchloride97%
• CAS NO: 65055-17-6
• Molecular Formula: C₇H₃Cl₂FO
• Molecular Weight: 193
• Product Categories: ACIDHALIDE;Aromatic Halides (substituted);Fluorine series
• Mol File: 65055-17-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 28 °C
• Boiling Point: 222 °C
• Flash Point: 222°C
• Appearance: low-melting solid
• Density: 1.46
• Vapor Pressure: 0.142mmHg at 25°C
• Refractive Index: 1.551
• Sensitive: Moisture Sensitive
• BRN: 6288904
• CAS DataBase Reference: 3-Chloro-4-fluorobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-4-fluorobenzoyl chloride(65055-17-6)
• EPA Substance Registry System: 3-Chloro-4-fluorobenzoyl chloride(65055-17-6)

Safety Data

• Hazard Codes: C,Xi,Xn
• Statements: 34-22
• Safety Statements: 26-36/37/39-45-27
• RIDADR: 3265
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 65055-17-6(Hazardous Substances Data)

Usage

Uses

3-Chloro-4-fluorobenzoyl chloride is a useful reactant, and has been used in the synthesis of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.

InChI:InChI=1/C7H3Cl2FO/c8-5-3-4(7(9)11)1-2-6(5)10/h1-3H

Upstream product

• 403-16-7 3-chloro-4-fluorobenzoic acid 
• 403-43-0 4-fluorobenzoyl chloride 

Downstream Products

• 65054-79-7 2-(3-Chloro-4-fluoro-benzoylamino)-4-methylsulfanyl-butyric acid 
• 403-16-7 3-chloro-4-fluorobenzoic acid 
• 1422376-82-6 methyl 2-(3-chloro-4-fluorobenzoyl)-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole-3-carboxylate 
• 1395412-10-8 3-chloro-4-fluoro-N-methyl-N-(4-o-tolyl-pyridin-3-yl)-benzamide 
• 1383256-08-3 3-(3-chloro-4-fluorobenzoyl)-2,3-dihydrobenzo[d]thiazole-2-carbonitrile 
• 1363188-90-2 3-(3'-chloro-4'-fluorophenyl)isocoumarin 
• 325458-27-3 N-(6-chloropyridin-3-yl)-3-chloro-4-fluorobenzamide 
• 869990-62-5 tert-butyl 4-[(3-chloro-4-fluorobenzoyl)amino]piperidine-1-carboxylate 
• 929291-96-3 3-Chloro-4-fluoro-benzoic acid 5-(3-chloro-4-fluoro-benzoylamino)-2-methyl-phenyl ester 
• 234082-35-0 methyl 3-chloro-4-fluorobenzoate 
• 871096-25-2 2-[(3-chloro-4-fluorobenzoyl)amino]-1,3-thiazole-4-carboxylic acid 

Relevant articles and documents

Cyano-and ketone-containing selenoesters as multi-target compounds against resistant cancers

Fifteen selenocompounds, comprising of eight ketone-containing selenoesters (K1–K8, also known as oxoselenoesters) and seven cyano-containing selenoesters (N1–N7, known also as cyanoselenoesters), have been designed, synthesized, and evaluated as novel anticancer agents. These compounds are derivatives of previously reported active selenoesters and were prepared following a three-step one-pot synthetic route. The following evaluations were performed in their biological assessment: cytotoxicity determination, selectivity towards cancer cells in respect to non-cancer cells, checkerboard combination assay, ABCB1 inhibition and inhibition of ABCB1 ATPase activity, apoptosis induction, and wound healing assay. As key results, all the compounds showed cytotoxicity against cancer cells at low micromolar concentrations, with cyanoselenoesters being strongly selective. All of the oxoselenoesters, except K4, were potent ABCB1 inhibitors, and two of them, namely K5 and K6, enhanced the activity of doxorubicin in a synergistic manner. The majority of these ketone derivatives modulated the ATPase activity, showed wound healing activity, and induced apoptosis, with K3 being the most potent, with a potency close to that of the reference compound. To summarize, these novel derivatives have promising multi-target activity, and are worthy to be studied more in-depth in future works to gain a greater understanding of their potential applications against cancer.

Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds

Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.

Studies on phenothiazines: New microtubule-interacting compounds with phenothiazine A-ring as potent antineoplastic agents

New phenothiazine derivatives 6-20 have been designed, synthesized and evaluated in vitro for their ability to inhibit tubulin polymerization and antiproliferative activity against 60 cancer cell lines, including several multi-drug resistant (MDR) tumor cell lines. The phenothiazine unit may successfully replace the classical 3,4,5-trimethoxyphenyle A ring of parent combretastatin A-4 or phenstatin, confirming previous studies. The most promising structural modulations have been realized on the B ring, the 2′-fluoro-4′-methoxy substitution in compound 6 and the 2′-trifluoromethyl-4′-methoxy substitution in compound 7 providing the best antitubulin and antitumor activity in the current study. Compounds 6-8 and 16 exhibited more important cell growth inhibition than parent phenstatin 2 on human colon Duke's type D, colorectal adenocarcinoma COLO 205 and on human kidney adenocarcinoma A498 cell lines. 10-Methylphenothiazine derivatives 19 and 20 did not show biological activity but exerted bright fluorescence and solvatochromism effects. These molecules deserve further chemical efforts in order to provide valuable tools for biophysical studies.